Investors

2018 News

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/08/18Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results
REDWOOD CITY, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018.   Second Quarter 2018 Corporate Highlights Include: UDENYCA™ (pegfilgrastim-cbqv), biosimilar candidate to Neulasta®           •  On May 3, 2018, Coherus announced the re-submission of its biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) under the 351(k... 
Printer Friendly Version
07/27/18Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ (Pegfilgrastim Biosimilar Candidate)
REDWOOD CITY, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®1) biosimilar candidate. UDENYCA has the opportunity to become one of the first pegfilgrastim biosimilars to gain Marketing Authorization in Europe. "The positive ... 
Printer Friendly Version
07/25/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective July 19, 2018, the compensation committee of the company’s board of directors granted 11 new employees options to purchase an aggregate of 167,500 shares of the company’s common stock with a per share exercise price of $18.45, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commence... 
Printer Friendly Version
07/24/18Coherus BioSciences to Report Second Quarter 2018 Financial Results on August 8th
REDWOOD CITY, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2018 financial results will be released after market close on Wednesday, August 8, 2018.  Starting at 4:30 p.m. ET, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing second quarter 2018 financial results, we will post them on the Coherus website at http://investors.cohe... 
Printer Friendly Version
06/22/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective June 21, 2018, the compensation committee of the company’s board of directors granted 8 new employees options to purchase an aggregate of 142,000 shares of the company’s common stock with a per share exercise price of $16.30, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencem... 
Printer Friendly Version
05/25/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., May 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective May 23, 2018, the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 61,000 shares of the company’s common stock with a per share exercise price of $15.30, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement... 
Printer Friendly Version
05/22/18Coherus Prices Public Offering of Common Stock
REDWOOD CITY, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced the pricing of its underwritten public offering of 5,172,413 shares of its common stock at a price to the public of $14.50 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 775,861 shares of its common stock at the public offering pric... 
Printer Friendly Version
05/21/18Coherus Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock at the public offering price, less the underwriting d... 
Printer Friendly Version
05/14/18U.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the U.S. Food and Drug Administration (FDA) has accepted and acknowledged for review the re-submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate.  In the communication, FDA indicated that they consider the resubmission a complete response to their June 9, 2017 action letter.  FDA provided a biosimilar user fee act (BSUFA... 
Printer Friendly Version
05/10/18Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2018.   First Quarter 2018 Corporate Highlights Include: Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) Announced on March 26, 2018, that Judge Stark of the United States District Court for the District of Delaware adopted Magistrate Judge Bur... 
Printer Friendly Version
05/10/18Coherus BioSciences Appoints Samuel Nussbaum, M.D. to Board of Directors
REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Samuel Nussbaum, M.D. to its Board of Directors.   “We are thrilled to have a health care policy and payer expert of Dr. Nussbaum’s stature join the Coherus Board of Directors. Recent introductions of therapeutic biologics and biosimilars to the U.S. market, have highlighted the importance of a robust market access strategy and execution. Dr. Nussbaum’s distingu... 
Printer Friendly Version
05/03/18Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
REDWOOD CITY, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the re-submission of its biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to the U.S. FDA under the 351(k) pathway. The BLA is supported by similarity data from analytical, pharmacokinetic, pharmacodynamics, and immunogenicity studies comparing CHS-1701 and Neulasta and integrates new immunogenicity data obtained from using a more... 
Printer Friendly Version
05/01/18Coherus BioSciences Management to Present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada
REDWOOD CITY, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas, Nevada. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a leading pure-p... 
Printer Friendly Version
04/24/18Coherus BioSciences to Report First Quarter 2018 Financial Results on May 10th  
REDWOOD CITY, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018.  Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing first quarter 2018 financial results, we will post them on the Coherus BioSciences website at http://inves... 
Printer Friendly Version
04/19/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective April 19, 2018, the compensation committee of the company’s board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the company’s common stock with a per share exercise price of $12.05, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commenc... 
Printer Friendly Version
04/02/18Coherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco
REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the H.C. Wainwright Annual Life Sciences Conference on Tuesday, April 10, 2018 at 8:10 am ET being held in Monte Carlo, Monaco. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a leading pure-pla... 
Printer Friendly Version
03/13/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective March 12, 2018, the compensation committee of the company’s board of directors granted 2 new employees options to purchase an aggregate of 37,000 shares of the company’s common stock with a per share exercise price of $12.45, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencem... 
Printer Friendly Version
03/08/18Coherus BioSciences Reports Fourth Quarter and Full Year 2017 Financial Results
REDWOOD CITY, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2017.   Fourth Quarter and Full Year 2017 Financial Results: Research and development (R&D) expenses for the fourth quarter of 2017 were $31.5 million compared to $59.0 million for the same period in 2016.  R&D expenses for the fiscal year 2017 were $162.4 million, as com... 
Printer Friendly Version
03/01/18Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
REDWOOD CITY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at two upcoming investor healthcare conferences. Management participation in a fireside chat at the 38th Cowen & Company Healthcare Conference on Monday, March 12th at 2:50 p.m. ET taking place in Boston, MA. Management participation in a fireside chat is scheduled at Barclays Global Healthcare Conference on Wednesday, March 14th at ... 
Printer Friendly Version
02/27/18Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th
REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018.  At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.   After releasing fourth quarter and full year 2017 financial results, we will post them on the Coherus BioSc... 
Printer Friendly Version
01/02/18Coherus BioSciences Management to Present at The 36th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th annual J.P. Morgan healthcare conference on Monday, January 8, 2017 at 2:00 p.m. PT being held in San Francisco. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a leading pure-play, global bi... 
Printer Friendly Version